NOVNN Stock Chart & Stats
$2487.40
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$2,188.90 - $2,921.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$4.96T
Enterprise Value$275.93K
Total Cash (Recent Filing)$7.71B
Total Debt (Recent Filing)$49.15B
Price to Earnings (P/E)23.5
Beta0.26
Next Earnings
Oct 27, 2026EPS Estimate
39.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.59
Shares Outstanding2,034,819,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)5.81
Price to Sales (P/S)4.69
P/FCF Ratio14.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,776.09Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)186.86
Revenue Forecast (FY)$1.21T
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & High MarginsHigh reported margins and ~ $16B trailing free cash flow provide durable funding for R&D, launches, and shareholder returns. Robust cash generation cushions against revenue volatility, supports continued investment in priority franchises, and preserves strategic flexibility despite a modest FCF decline.
Multiple High‑growth Launches & Diversified Growth DriversA broad set of priority brands (Kisqali, Scemblix, LEQVIO, PLUVICTO, Kesimpta) showing sustained double‑digit growth reduces single‑product dependence. Diversified, accelerating launches improve probability of replacing lost exclusivity and support multi‑region revenue resilience over the medium term.
De‑risking Pipeline And Regulatory ProgressConcrete regulatory milestones (accelerated FDA submission, meaningful OS readouts) and visible gene‑therapy commercialization plans materially de‑risk future approvals. Successful readouts/submissions would expand addressable markets and underpin multi‑year revenue upside from late‑stage assets.
Bears Say
Rising Financial LeverageDebt increasing to roughly $49B and debt/equity ~1.22x meaningfully raises leverage. Higher indebtedness reduces financial flexibility for M&A or cushioning operational setbacks, increases refinancing and interest sensitivity, and amplifies downside if cash flows or launch trajectories weaken.
Significant Generic Erosion (Entresto)Entresto's loss of exclusivity created a material revenue and comparability headwind (~$800M in the Q3 base), compressing near‑term sales and margins. Sustained generic pressure requires successful new launches to offset recurring revenue declines, raising replacement risk over the medium term.
Execution & Regulatory Dependence; Margin Phasing RiskReliance on multiple pivotal readouts and regulatory decisions concentrates binary execution risk: delayed or negative outcomes would materially affect medium‑term growth. Additionally, one‑time phasing and Avidity‑related costs that boosted Q2 margins will reverse, creating potential H2 margin pressure.
Novartis AG News
NOVNN FAQ
What was Novartis’s price range in the past 12 months?
Novartis lowest stock price was $2188.90 and its highest was $2921.51 in the past 12 months.
What is Novartis’s market cap?
Novartis’s market cap is $4.96T.
When is Novartis’s upcoming earnings report date?
Novartis’s upcoming earnings report date is Oct 27, 2026 which is in 92 days.
How were Novartis’s earnings last quarter?
Novartis released its earnings results on Jul 21, 2026. The company reported $41.924 earnings per share for the quarter, beating the consensus estimate of $37.714 by $4.21.
Is Novartis overvalued?
According to Wall Street analysts Novartis’s price is currently Undervalued.
Does Novartis pay dividends?
Novartis does not currently pay dividends.
What is Novartis’s EPS estimate?
Novartis’s EPS estimate is 39.14.
How many shares outstanding does Novartis have?
Novartis has 2,034,819,500 shares outstanding.
What happened to Novartis’s price movement after its last earnings report?
Novartis reported an EPS of $41.924 in its last earnings report, beating expectations of $37.714. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novartis?
Currently, no hedge funds are holding shares in MX:NOVNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novartis
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOVNN Stock 12 Month Forecast
Average Price Target
$2,776.09